Alnylam's AMVUTTRA Gets Approval In Europe To Treat Hereditary Transthyretin-mediated Amyloidosis

BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - RNAi therapeutics company Alnylam Pharmaceuticals, Inc. (ALNY) announced Tuesday that the European Commission has granted marketing authorization for AMVUTTRA

Related Keywords

Saclay ,France General ,France ,Japan ,Paris ,Brussels ,Bruxelles Capitale ,Belgium ,Brazil ,Japanese ,Brazilian ,David Adams ,Head Of The Neurology Department ,European Commission ,Drug Administration ,Alnylam Pharmaceuticals Inc ,Brazilian Health Regulatory Agency ,Japanese Pharmaceuticals ,European Union ,University Of Paris ,Devices Agency ,Alnylam Pharmaceuticals ,Lead Investigator ,Orphan Drug Designation ,Medical Devices ,Alnylam ,Amvuttra ,Jets ,Approval ,Europe ,Treat ,Hereditary ,Transthyretin ,Unmediated ,Amyloidosis ,